Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generic Review Times, Medicaid Rebates On 2007 HHS OIG Agenda

Executive Summary

Up to speed on OGD: HHS Office of the Inspector General will continue to "determine the extent to which FDA reviews applications for generic drugs in a thorough and timely manner within statutory requirements" and examine what savings were lost by Medicaid in 2004 and 2005 due to the lack of generic availability, according to the office's 2007 FY 1Work Plan. OIG maintains that the average review time for generic drug applications exceeds 20 months, well beyond the 180-day statutory limit. According to the work plan, the delays have resulted in a backlog of approximately 1,000 applications, with 250 exceeding the 180-day limit. FDA has downplayed concerns over the backlog, but the agency projects the median ANDA review time to increase from 16.9 months in 2006 to 17.5 months in 2007 (2"The Pink Sheet" Feb. 13, 2006, p. 7)...

You may also be interested in...



Democratic Capitol Hill Will Create Challenges For Brand Industry

The sweep of both houses of Congress in the midterm elections will allow the Democrats the opportunity to push their agenda through must-pass legislation such as the reauthorization of the Prescription Drug User Fee Act

Democratic Capitol Hill Will Create Challenges For Brand Industry

The sweep of both houses of Congress in the midterm elections will allow the Democrats the opportunity to push their agenda through must-pass legislation such as the reauthorization of the Prescription Drug User Fee Act

Too Much Leeway? OIG Gives CMS Broad Advice For Medicaid Pricing Reg

CMS retains broad latitude in determining how average manufacturer price will be calculated after the HHS Office of the Inspector General did not make specific recommendations in a May 30 report

Related Content

UsernamePublicRestriction

Register

PS047660

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel